CBD (cannabidiol) is a phytocannabinoid without psychoactive effect derived from hemp plant (Cannabis Sativa). Medical and biological researches conducted in the past 10-15 years suggest that the use of CBD is harmless to the human body. As a matter of fact, CBD is an active component of two medicaments (Sativex(R) and Epidiolex(R)) that have been approved by the Federal Drug Agency (FDA) and the European Medicines Agency which supports its potential beneficial effects.

The structure of phytocannabinoids is very similar to the endocannabinoid molecules present in the human body which explains why they stimulate the receptors of the endocannabinoid system (ECS). The ECS is involved in regulating mental and physical responses of the body to stress and anxiety, affects the activity of the immune system, regulates the body temperature, the sleep cycle and other physiological functions. Therapies targeting the endocannabinoid system are getting more and more attention in pharmaceutical researches recently. Two primary receptors have been identified (CB1 & CB2) through which the endo- and phytocannabinoids can stimulate the organism.

CB1 receptors are found predominantly in the brain and nervous system, while CB2 receptors in the immune and digestive system. Various cannabidiols might have different

effect as a result of the diversity in their structure which determines the chemical bond they build. Nevertheless, CBD is a phytocannabinoid that might support or block the effects of compounds in the endocannabinoid system. Besides, CBD can stimulate CB1 and CB2 receptors without having any psychoactive effect. 

Not only the endocannabinoid system might benefit from CBD:

  • It might help release serotonin in the human body which is responsible for our good mood and feeling of happiness
  • It might have beneficial effects on TRP channels that mediate a variety of sensations like pain and temperature
  • It might support the metabolism of kidneys through the PPAR-alpha channels

According to the publication released by WHO CBD might ease spasm-type seizures and anxiety, it has anti-inflammatory properties, might improve the quality of sleep and might block the growth of cancer cells. Researches have demonstrated that CBD can reduce or even cease the symptoms of epilepsy. Further on, there seem to be evidences about the antipsychotic properties of CBD (see section The benefits of CBD).

CBD can be found in several different products (e.g. oils, capsules, cremes) that can generally be categorized into 3 types.

CBD isolate

This form of extract contains CBD molecules and the carrier only which is mostly some kind of a vegetable oil. In CeBDon products we use extra virgin cold pressed organic hemp seed carrier oil exclusively. Test case results show that products containing solely CBD might have less advantages and decreased efficiency compared to the broad or full spectrum products.

Broad spectrum formula

Besides CBD it contains other natural substances with beneficial physiological effects like phytocannabinoids (Other phytocannabinoids) (CBN, CBG, CBC), terpenoids, flavonoids which might be even more efficient together. The broad spectrum formula does not contain any THC at all.

Full spectrum formula

Alongside CBD it contains all the substances mentioned before (CBN, CBG, CBC, terpenoids, flavonoids) but also a small amount of tetrahydrocannabinol (THC) (Other phytocannabinoids) as well. The presence of a small amount of THC might contribute to the potential beneficial effects of the active substances mentioned before. Though it’s important that it contains less than 0.2% of THC as controlled by the regulations of the European Union since this amount of THC is far below the amount needed to produce psychotropic effects.

More info: